Similar articles

• Monoamine oxidase. II. Time-dependent inhibition by propargylamines.

  Williams CH, Lawson J. Williams CH, et al. Biochem Pharmacol. 1974 Feb 1;23(3):629-36. doi: 10.1016/0006-2952(74)90627-3. Biochem Pharmacol. 1974. PMID: 4822747 No abstract available.
• The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications.

  Fowler CJ, Oreland L, Callingham BA. Fowler CJ, et al. J Pharm Pharmacol. 1981 Jun;33(6):341-7. doi: 10.1111/j.2042-7158.1981.tb13800.x. J Pharm Pharmacol. 1981. PMID: 6115003 Review. No abstract available.
• Evidence for a specific monoamine oxidase associated with sympathetic nerves.

  Goridis C, Neff NH. Goridis C, et al. Neuropharmacology. 1971 Sep;10(5):557-64. doi: 10.1016/0028-3908(71)90021-9. Neuropharmacology. 1971. PMID: 5126693 No abstract available.
• N-substituted cyclopropylamines as monoamine oxidase inhibitors. Structure-activity relationships. Dopa potentiation in mice and in vitro inhibition of kynuramine oxidation.

  Mills J, Kattau R, Slater IH, Fuller RW. Mills J, et al. J Med Chem. 1968 Jan;11(1):95-7. doi: 10.1021/jm00307a021. J Med Chem. 1968. PMID: 4384132 No abstract available.
• Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs.

  Neff NH, Yang HY. Neff NH, et al. Life Sci. 1974 Jun 1;14(11):2061-74. doi: 10.1016/0024-3205(74)90089-7. Life Sci. 1974. PMID: 4603266 Review. No abstract available.